Pulmatrix Inc (PULM) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.44 (+0.50%), Market cap $0.00B, 52-week low–high $1.19 ~ $9.09.
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis;
Financial statements, price targets, institutional (13F) holdings and related news for Pulmatrix Inc are updated in real time on BlackAll Trade.
Pulmatrix Inc trades at $1.44 (+0.50%). Real-time quotes and charts are available on BlackAll Trade.
Pulmatrix Inc has a market cap of about $0.00B.
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United